Contigo launches new water bottle for kids
CHICAGO — Contigo has introduced a new spill-proof water bottle for kids.
The new, BPA-free Striker water bottle is designed for children ages 3 years and older and features an AutoSpout lid, which includes a kid-friendly push-to-drink button for easy one-handed drinking on the go. The bottle also features a specially designed spill-proof valve — the first AutoSpout water bottle with this feature — which helps kids transition from sippy cups without the mess.
Contigo’s new Striker water bottle is available in a 14-oz. size and carries a suggested retail price of $9.99.
Kalorama: Worldwide sales of flu vaccines dropped 30% from 2010 to 2011
NEW YORK — For the first time in a decade, sales of vaccines declined, Kalorama Information noted in a report released Thursday. A weak flu season last year was one factor that led to a 30% decline in the market to $19.8 billion in 2011, down from $24.1 billion in 2010. However, Kalorama projects that the world vaccines market will rebound — increasing at a compound annual rate of 8.9% during 2011-2016.
"What goes up must come down and so it is with vaccine sales," stated Bruce Carlson, publisher of Kalorama Information. "We should be clear that our estimate reflects overall vaccine sales, and these results mostly have to do with influenza and a few other categories and do not change the overall trend that pharmaceutical companies are heavily interested in vaccines as part of their growth strategies."
The report said that while sales of adult influenza vaccines had been strong in 2009 and 2010 due to government stockpiling — and in some cases, over-purchasing — of new avian and swine flu vaccines, sales have since returned to earlier, pre-pandemic levels. All of the major flu vaccine manufacturers reported significant declines from 2010.
FDA approves new cancer drug
SAN FRANCISCO — The Food and Drug Administration has approved a new drug for colorectal cancer developed by Bayer HealthCare.
Bayer and Onyx Pharmaceuticals announced the approval of Stivarga for colorectal cancer that has spread to other parts of the body, also known as metastatic CRC, specifically for those patients who have received treatment with currently available therapies.
Bayer developed the drug and will pay royalties to Onyx on future global net sales of the drug for cancer. The two companies will promote the drug together in the United States.